AR-targeting treatments are used in case of regional or advanced disease as primary systemic therapy, and as neoadjuvant/concomitant/adjuvant therapy to radiation therapy or surgery in localized or locally advanced PCa [1]. The gene discussed is AR; the disease is posterior cortical atrophy.